Evotec SE has made progress under a strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programs. Evotec receives a $25 million payment to progress further research. Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases that slow down or reverse disease progression. This progress leverages Evotec’s Pa...